Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 1187 | 5.85 |
09:34 ET | 424 | 5.86 |
09:36 ET | 300 | 5.8 |
09:39 ET | 3150 | 5.83 |
09:41 ET | 1462 | 5.84 |
09:43 ET | 100 | 5.83 |
09:45 ET | 700 | 5.8 |
09:52 ET | 200 | 5.82 |
09:54 ET | 282 | 5.8 |
09:56 ET | 100 | 5.8 |
10:01 ET | 700 | 5.76 |
10:03 ET | 200 | 5.735 |
10:08 ET | 1065 | 5.78 |
10:10 ET | 18330 | 5.775 |
10:12 ET | 577 | 5.73 |
10:15 ET | 100 | 5.75 |
10:17 ET | 100 | 5.75 |
10:19 ET | 3192 | 5.735 |
10:21 ET | 100 | 5.73 |
10:24 ET | 500 | 5.75 |
10:26 ET | 829 | 5.75 |
10:28 ET | 791 | 5.73 |
10:30 ET | 200 | 5.74 |
10:32 ET | 300 | 5.75 |
10:33 ET | 200 | 5.74 |
10:35 ET | 300 | 5.735 |
10:37 ET | 1498 | 5.76 |
10:39 ET | 200 | 5.75 |
10:42 ET | 600 | 5.76 |
10:44 ET | 332 | 5.78 |
10:46 ET | 395 | 5.77 |
10:48 ET | 222 | 5.76 |
10:50 ET | 100 | 5.76 |
10:51 ET | 1904 | 5.75 |
10:53 ET | 250 | 5.76 |
10:57 ET | 1778 | 5.7899 |
11:00 ET | 4750 | 5.8 |
11:02 ET | 850 | 5.85 |
11:04 ET | 1673 | 5.8499 |
11:06 ET | 1400 | 5.8 |
11:08 ET | 924 | 5.79 |
11:09 ET | 928 | 5.82 |
11:18 ET | 1400 | 5.83 |
11:20 ET | 1100 | 5.79 |
11:22 ET | 100 | 5.795 |
11:24 ET | 500 | 5.805 |
11:27 ET | 700 | 5.82 |
11:29 ET | 1400 | 5.83 |
11:31 ET | 970 | 5.87 |
11:33 ET | 300 | 5.85 |
11:36 ET | 200 | 5.8476 |
11:38 ET | 621 | 5.85 |
11:40 ET | 200 | 5.86 |
11:42 ET | 1900 | 5.88 |
11:44 ET | 400 | 5.8812 |
11:45 ET | 100 | 5.8601 |
11:47 ET | 1041 | 5.89 |
11:54 ET | 400 | 5.89 |
11:58 ET | 200 | 5.895 |
12:00 ET | 300 | 5.88 |
12:02 ET | 100 | 5.88 |
12:05 ET | 200 | 5.88 |
12:07 ET | 1096 | 5.86 |
12:09 ET | 100 | 5.85 |
12:12 ET | 753 | 5.87 |
12:16 ET | 100 | 5.87 |
12:20 ET | 206 | 5.86 |
12:23 ET | 371 | 5.87 |
12:25 ET | 800 | 5.85 |
12:27 ET | 700 | 5.85 |
12:32 ET | 200 | 5.845 |
12:34 ET | 1528 | 5.8599 |
12:38 ET | 400 | 5.86 |
12:39 ET | 600 | 5.86 |
12:41 ET | 100 | 5.86 |
12:43 ET | 346 | 5.85 |
12:54 ET | 227 | 5.86 |
12:56 ET | 300 | 5.865 |
12:59 ET | 168 | 5.85 |
01:03 ET | 11895 | 5.86 |
01:06 ET | 4667 | 5.86 |
01:08 ET | 11249 | 5.9 |
01:10 ET | 213 | 5.8901 |
01:12 ET | 2167 | 5.86 |
01:14 ET | 700 | 5.85 |
01:15 ET | 100 | 5.845 |
01:19 ET | 300 | 5.845 |
01:21 ET | 1124 | 5.84 |
01:24 ET | 2100 | 5.815 |
01:26 ET | 2880 | 5.79 |
01:28 ET | 300 | 5.795 |
01:30 ET | 6261 | 5.79 |
01:32 ET | 621 | 5.76 |
01:35 ET | 1995 | 5.79 |
01:37 ET | 1020 | 5.79 |
01:39 ET | 1328 | 5.8 |
01:44 ET | 100 | 5.78 |
01:50 ET | 1958 | 5.79 |
01:51 ET | 2305 | 5.78 |
02:00 ET | 700 | 5.77 |
02:02 ET | 200 | 5.76 |
02:04 ET | 912 | 5.78 |
02:08 ET | 600 | 5.77 |
02:11 ET | 400 | 5.78 |
02:13 ET | 100 | 5.785 |
02:15 ET | 600 | 5.79 |
02:18 ET | 100 | 5.79 |
02:20 ET | 400 | 5.78 |
02:22 ET | 300 | 5.79 |
02:24 ET | 831 | 5.79 |
02:26 ET | 960 | 5.7978 |
02:27 ET | 100 | 5.79 |
02:29 ET | 209 | 5.7801 |
02:31 ET | 2466 | 5.805 |
02:33 ET | 1170 | 5.84 |
02:36 ET | 100 | 5.86 |
02:40 ET | 870 | 5.87 |
02:42 ET | 1400 | 5.8642 |
02:44 ET | 1500 | 5.86 |
02:47 ET | 100 | 5.86 |
02:49 ET | 100 | 5.86 |
02:51 ET | 709 | 5.875 |
02:54 ET | 468 | 5.86 |
02:56 ET | 512 | 5.85 |
03:02 ET | 190 | 5.84 |
03:07 ET | 1707 | 5.83 |
03:12 ET | 500 | 5.82 |
03:14 ET | 606 | 5.81 |
03:16 ET | 500 | 5.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 209.3M | --- | --- |
ATAI Life Sciences NV | 204.2M | -3.4x | --- |
Trevi Therapeutics Inc | 201.1M | -7.6x | --- |
Rezolute Inc | 217.9M | -3.8x | --- |
Zura Bio Ltd | 220.4M | --- | --- |
Pyxis Oncology Inc | 198.0M | -2.9x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $209.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Biomea Fusion Inc does not pay a dividend. | |
Beta | -0.54 |
EPS | $-3.90 |
Book Value | $4.72 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.